IRVINE, CA / ACCESSWIRE / July 17, 2017 / Khang & Khang LLP (the "Firm") announces a securities class action lawsuit against Roche Holding AG ("Roche Holding" or the "Company") (OTCQX: RHHBY). Investors, who purchased or otherwise acquired shares from March 2, 2017 through June 5, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm before the August 7, 2017 lead plaintiff motion deadline.
If you purchased shares of Roche Holding during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.
According to the Complaint, throughout the Class Period, Roche Holding issued materially false and misleading statements and/or failed to disclose material information, specifically that the combination of the Company's breast cancer drug, Perjeta, and its older treatment, Herceptin, is only marginally more effective than Herceptin alone in preventing breast cancer, and has a higher rate of side effects. Following this news, Roche Holding's stock price dropped materially, causing investors harm according to the Complaint.
If you want to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Joon M. Khang, Esq.
SOURCE: Khang & Khang LLP